Low dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients.
Akihiko MitsukeTakahiko OhboJunya ArimaYoichi OsakoTakashi SakaguchiRyosuke MatsushitaHirofumi YoshinoShuichi TataranoYasutoshi YamadaHajime SasakiTatsu TanabeNobuyuki FukuzawaHiroshi TanakaYoshihiko NishioEnokida HidekiHiroshi HaradaPublished in: PloS one (2023)
The development of diabetes mellitus (DM) after living donor kidney transplantation (KT) is a risk factor for worsening transplant kidney function, cardiac disease, and cerebrovascular disease, which may affect prognosis after KT. At our institution, all patients' glucose tolerance is evaluated perioperatively by oral glucose tolerance tests (OGTTs) at pre-KT, and 3, 6, and 12 month (mo.) after KT. We analyzed the insulinogenic index (ISI) and homeostasis model assessment beta cell (HOMA-β) based on the immunoreactive insulin (IRI) levels to determine how glucose tolerance changed after KT in 214 patients who had not been diagnosed with DM before KT. In addition, we analyzed the body mass index (BMI) which may also influence glucose tolerance after KT. The concentration of tacrolimus (TAC) in blood was also measured as the area under the curve (AUC) to examine its effects at each sampling point. The preoperative-OGTTs showed that DM was newly diagnosed in 22 of 214 patients (10.3%) who had not been given a diagnosis of DM by the pre-KT fasting blood sugar (FBS) tests. The glucose tolerance was improved in 15 of 22 DM patients at 12 mo. after KT. ISI and IRI deteriorated only at 3 mo. after KT but improved over time. There was a trend of an inverse correlation between HOMA-β and TAC-AUC. We also found inverse correlations between IRI and an increase in BMI from 3 to 12 mo. after KT. Early corticosteroid withdrawal or the steroid minimization protocol with tacrolimus to maintain a low level of diabetogenic tacrolimus and BMI decrease after KT used by our hospital individualizes lifestyle interventions for each patient might contribute to an improvement in post-KT glucose tolerance.
Keyphrases
- body mass index
- newly diagnosed
- low dose
- type diabetes
- glycemic control
- randomized controlled trial
- kidney transplantation
- body weight
- weight gain
- emergency department
- healthcare
- stem cells
- weight loss
- patients undergoing
- heart failure
- left ventricular
- high dose
- chronic kidney disease
- blood glucose
- cell therapy
- atrial fibrillation
- patient reported outcomes